These final results, together with a previous report demonstrating that a small-molecule ACKR3 agonist CCX771 exhibits anxiolytic-like habits in mice,two support the thought of concentrating on ACKR3 as a singular strategy to modulate the opioid program, which could open up new therapeutic avenu